| First Author | Suzuki A | Year | 1997 |
| Journal | Genes Dev | Volume | 11 |
| Issue | 10 | Pages | 1242-52 |
| PubMed ID | 9171369 | Mgi Jnum | J:40595 |
| Mgi Id | MGI:707943 | Doi | 10.1101/gad.11.10.1242 |
| Citation | Suzuki A, et al. (1997) Brca2 is required for embryonic cellular proliferation in the mouse. Genes Dev 11(10):1242-52 |
| abstractText | Mutations of the tumor suppressor gene BRCA2 are associated with predisposition to breast and other cancers. Homozygous mutant mice in which exons 10 and 11 of the Brca2 gene were deleted by gene targeting (Brca2(10- 11)) die before day 9.5 of embryogenesis. Mutant phenotypes range from severely developmentally retarded embryos that do not gastrulate to embryos with reduced size that make mesoderm and survive until 8.5 days of development, Although apoptosis is normal, cellular proliferation is impaired in Brca2(10-11) mutants, both in vivo and in vitro. In addition, the expression of the cyclin-dependent kinase inhibitor p21 is increased. Thus, Brca2(10-11) mutants are similar in phenotype to Brca1(5- 6) mutants but less severely affected. Expression of either of these two genes was unaffected in mutant embryos of the other. This study shows that Brca2, like Brca1, is required for cellular proliferation during embryogenesis. The similarity in phenotype between Brca1 and Brca2 mutants suggests that these genes may have cooperative roles or convergent functions during embryogenesis. |
